Medicenna Therapeutics (NASDAQ:MDNA) Announces Earnings Results, Misses Expectations By $0.02 EPS

Medicenna Therapeutics (NASDAQ:MDNA) posted its earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.02), reports.

MDNA opened at $3.72 on Monday. The business’s 50 day simple moving average is $4.03. The firm has a market cap of $182.00 million, a P/E ratio of -19.58 and a beta of 1.81. Medicenna Therapeutics has a 1 year low of $0.98 and a 1 year high of $5.32.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.

Read More: Stock Portfolio Tracker

Earnings History for Medicenna Therapeutics (NASDAQ:MDNA)

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.